Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDH8 antisense RNA 1 (CDH8-AS1) is presumed to be a long non-coding RNA transcript that is transcribed antisense to the CDH8 gene. Long non-coding RNAs (lncRNAs), in general, are RNA molecules longer than 200 nucleotides that do not code for proteins but can have regulatory functions in gene expression. However, there is very limited, if any, peer-reviewed literature or curated database evidence describing the specific function, molecular classification, disease relevance, or drug interactions of CDH8-AS1. Most available information about the region concerns CDH8, a cadherin family protein involved in cell adhesion during development. The term CDH8-AS1 may be referenced in some genomic databases as a predicted or uncharacterized lncRNA, but as of now, it is not established as a therapeutic target, biomarker, or disease-associated molecule in publicly available scientific literature. If your intent was to refer to the well-characterized CHD8 (chromodomain helicase DNA binding protein 8), there are abundant data linking it to neurodevelopment, autism, chromatin remodeling, and gene regulation[1][2][3][4][5]. However, "CDH8-AS1" specifically appears to be either: - Not a well-characterized entity in scientific literature, - Or, potentially misspelled or confused with "CHD8" or "CDH8". Recommendation: For structured annotation and downstream applications, treat "CDH8-AS1" as insufficiently defined or not a current valid therapeutic target. If you need information about CHD8 or CDH8 (cadherin 8 protein), please clarify for detailed, accurate coverage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDH8 antisense RNA 1 (CDH8-AS1).